Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia

Background Methotrexate is an important component of curative therapy in childhood acute lymphoblastic leukemia (ALL), but the role of genetic variation influencing methotrexate clearance and transport in toxicity susceptibility in children with ALL is not well established. Therefore, we evaluated t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmacotherapy 2025-01, Vol.45 (1), p.4-11
Hauptverfasser:	Harris, Rachel D., Taylor, Olga A., Gramatges, M. Monica, Hughes, Amy E., Zobeck, Mark, Pruitt, Sandi, Bernhardt, M. Brooke, Chavana, Ashley, Huynh, Van, Ludwig, Kathleen, Klesse, Laura, Heym, Kenneth, Griffin, Timothy, Erana, Rodrigo, Bernini, Juan Carlos, Choi, Ashley, Ohno, Yuu, Richard, Melissa A., Morrison, Alanna C., Chen, Han, Yu, Bing, Lupo, Philip J., Rabin, Karen, Scheurer, Michael E., Brown, Austin L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute lymphoblastic leukemia Adolescent Alleles Antimetabolites, Antineoplastic - adverse effects Child Child, Preschool Children epidemiology Female Genetic diversity Humans Leukemia Lymphatic leukemia Male Medical records Methotrexate Methotrexate - adverse effects Methotrexate - therapeutic use Multidrug Resistance-Associated Protein 2 Multidrug Resistance-Associated Proteins - genetics Neurotoxicity Neurotoxicity Syndromes - etiology Neurotoxicity Syndromes - genetics oncology Pediatrics pharmacoepidemiology Pharmacogenetics Pharmacogenomic Variants Pharmacogenomics Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics Statistical models Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!